|University of Michigan, BS|
|Harvard Business School, MBA|
Mr. Kaul is a founding general partner at Khosla Ventures along with Vinod Khosla, focusing primarily on renewable energy, clean technologies, and life sciences investing. Since joining forces with Khosla, Mr. Kaul has been a cofounder/founding investor in Calera, Cogenra, CoSkata, Gevo (GEVO), Kior (KIOR), Lanza, Sakti3; he has also led the firm’s investments in Amyris (AMRS), Ausra (acquired by Areva), Draths (acquired by Amyris), PRAJ Industries (BSE:PRAJ), Stion, Transonic Combustion, Segetis, NanoH20, View, and a number of early-stage science projects.
Previously, Mr. Kaul was with Flagship Ventures where he started and invested in early-stage biotechnology companies. During his five years there, Mr. Kaul was involved in starting and investing in a number of companies including Helicos BioSciences (NASDAQ: HLCS), Epitome (acquired by Millipore), Codon Devices, LS9, and Morphotek (acquired by Eisai).
Mr. Kaul began his career at the Venter’s Institute for Genomic Research (TIGR). He joined TIGR to work on the genome of Arabidopsis thaliana, a member of the mustard family, which was a model organism for understanding agricultural staples such as rice, corn, and wheat. Soon Mr. Kaul was promoted to run the project both within TIGR and internationally as the chairperson of the Arabidopsis Genome Initiative (AGI).
Mr. Kaul holds a MBA from Harvard Business School. He attended the University of Michigan, where he majored in biology and taught undergraduate biochemistry and then continued on to graduate school to study biochemistry at the University of Maryland.